Formulation Development
WHITEPAPER - Container Selection for a Highly Sensitive Drug Product: A Success Story
When Stevanato Group is involved from the early stages, before the container is even chosen, we can support the client with a comprehensive data-driven analysis so the client can make an informed choice and select the optimal solution for their drug product.
Lifecore Biomedical Names New Chief Commercial Officer
Lifecore Biomedical, Inc. recently announced it has appointed Mark DaFonseca as chief commercial officer. A seasoned CDMO and pharmaceutical services executive, Mr. DaFonseca has nearly…
XOMA Royalty Purchases Mezagitamab Royalty & Milestone Rights Held by BioInvent International for up to $30 Million
XOMA Royalty Corporation and BioInvent International AB recently announced XOMA Royalty has purchased the future mezagitamab (TAK-079) royalty and milestone interests held by BioInvent for…
GRIN Therapeutics & Angelini Pharma Enter Exclusive Collaboration to Develop & Commercialize Radiprodil Outside North America
GRIN Therapeutics, Inc. and Angelini Pharma recently announced a collaboration for the development and commercial rights outside of North America of GRIN Therapeutic's investigational drug radiprodil,…
Vetter Once Again Named Best Managed Company
Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), has been named Best Managed Company in its anniversary year for the sixth time in…
Altamira Therapeutics Announces Collaboration on Circular RNA Delivery
Altamira Therapeutics Ltd. recently announced it has entered into a collaboration agreement with an undisclosed company to evaluate the potential use of Altamira’s proprietary CycloPhore…
Rein Therapeutics Announces First Patient Dosed in Phase 2 Trial of LTI-03 in Patients With IPF
Rein Therapeutics recently announced the first patient has been dosed in the RENEW Phase 2 trial of its lead asset, LTI-03, a novel, multi-pathway, Caveolin-1-related…
IMUNON Announces Oral Presentation Highlighting Unprecedented Survival Data From Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer
IMUNON recently announced new positive data from its Phase 2 OVATION 2 Study of IMNN-001, an investigational therapy for the treatment of advanced ovarian cancer.…
WHITEPAPER: Partnering With Gattefossé to Tackle Veterinary Medicine Challenges
Veterinary medicines face unique challenges due to species diversity, physiology, and dosing needs. Animals can’t be instructed to take medicine, so palatability, safety, and bioavailability are key.
Lonza Launches Design2Optimize Platform to Streamline API Development
Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), announced today the launch of its new Design2Optimize platform to enhance process development…
Sanofi to Acquire Vigil Neuroscience, Adding a New Investigational Medicine to Treat Alzheimer’s Disease
Sanofi recently announced it has entered into an agreement to acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies…
Amphista Therapeutics Showcases Cryo-EM Enabled Platform for Discovering Novel Targeted Glue Degraders
Amphista Therapeutics presented its unique approach to constructing novel, orally bioavailable Targeted Glue protein degraders with mechanisms of action (MoA) distinct from traditional CRBN/VHL approaches…
Belite Bio Announces Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease
Belite Bio, Inc. recently announced the US FDA has granted Breakthrough Therapy Designation for Tinlarebant for the treatment of Stargardt disease (STGD1) based on the…
Kaida BioPharma Announces New Partnership With Northway Biotech for the Manufacturing of KAD101
Kaida BioPharma recently announced it has entered into a manufacturing agreement with Northway Biotech, Inc. for the manufacturing of lead product candidate, KAD101. Under the…
Montara Therapeutics to Develop Novel Treatments Using the BrainOnly Platform
Montara Therapeutics recently announced it has received a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in addition to joining MJFF’s…
Philikos Announces Initiation of Clinical Phase 1/2 Study With T-Guard in Patients With Systemic Sclerosis
Philikos B.V. recently announced it has enrolled the first patient in a Phase 1/2 clinical trial designed to evaluate the use of T-Guard for the…
CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing
CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, has chosen CELLforCURE by SEQENS, as its contract development and manufacturing organization (CDMO) partner for…
GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing & Evidence of Early Immune Activation Signals
GT Biopharma, Inc. recently announced successful completion of dosing in Cohort 1 and subsequent initiation of dosing in Cohort 2 of its Phase 1 dose escalation…
Fujifilm Validates Cancer Cell-Targeting Potential of Peptide Oligonucleotide Conjugates With Novel Cyclic Peptides
FUJIFILM Corporation announces the successful validation of the cancer cell-targeting potential of its peptide-oligonucleotide conjugates. This validation resulted from combining oligonucleotides with cyclic peptides developed…
SISCAPA & Biognosys Announce Strategic Collaboration to Deliver End-to-End High-Sensitivity Targeted Protein Quantification Solutions
SISCAPA Assay Technologies and Biognosys recently announced an exclusive strategic collaboration to offer biopharma customers a streamlined end-to-end solution for high-sensitivity protein analysis—from early protein…
